Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 10/20 | 0.39 |
| ▸ | ADH5 | P11766 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907429 | 0.87 | ALOX15 (0.37) | RORCKDM4C | |
| SCHEMBL9907917 | 0.85 | HTR5A (0.51) | PLAU | |
| SCHEMBL9907375 | 0.82 | KMO (0.53) | PLAURORCCSNK2A2CSNK2BKDM5A | |
| SCHEMBL9909227 | 0.79 | SLC22A12 (0.47) | PLAURORCADH5CSNK2A2CSNK2B | |
| SCHEMBL9907384 | 0.77 | PLAU (0.46) | PLAUCSNK2A2CSNK2BKDM4AKDM5A | |
| SCHEMBL9907395 | 0.77 | PLAU (0.43) | PLAUCSNK2A2CSNK2BKDM4CKDM5B | |
| SCHEMBL9907603 | 0.74 | HTR5A (0.55) | RORCCSNK2A2CSNK2BAXLPPARG | |
| SCHEMBL9907318 | 0.74 | PLAU (0.50) | PLAUCSNK2A2CSNK2BKDM4AKDM5A | |
| SCHEMBL9907693 | 0.74 | PLAU (0.50) | PLAURORCCSNK2A2CSNK2BKDM4A | |
| Hydrochloric Acid SCHEMBL9108278 | 0.73 | PLAU (0.49) | PLAUCSNK2A2CSNK2BKDM4AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PLAU 3322/4885RORC 3704/4885ADH5 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.